INDIANAPOLIS, May 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from 57 studies at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 4 – 8, 2010, during which the company will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine HCl for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and Merck-Serono.
Of note are two Phase II ALIMTA studies (ASCO Abstracts #7082 and #7087), which both evaluate ALIMTA plus platinum-based chemotherapy in combination with concurrent radiation therapy in patients with advanced non-small cell lung cancer (NSCLC). Several studies evaluating GEMZAR in combination with other potential therapies are also slated for presentation at the meeting.
"Lilly Oncology research teams around the world are committed to finding new ways to improve and prolong the lives of people living with cancer," said John H. Johnson, president of Lilly Oncology. "We are constantly studying new uses for our established therapies and discovering new molecules – all in the hopes of changing the way we treat cancer."
In addition to studies on marketed Lilly Oncology products, new data will also be presented at ASCO on several Lilly Oncology molecules in clinical development, namely tasisulam (an anti-cancer agent), and ImClone's ramucirumab and cixutumumab (both are IgG1 monoclonal antibodies).
Studies of note for ALIMTA include:
|SOURCE Eli Lilly and Company|
Copyright©2010 PR Newswire.
All rights reserved